AHA: No Real Benefit Seen for Liberal Transfusion Strategy in AMI, Anemia
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 14, 2023 -- For patients with acute myocardial infarction and anemia, a liberal transfusion strategy does not significantly reduce the risk for recurrent myocardial infarction or death compared with a restrictive strategy, according to a study published online Nov. 11 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2023, held from Nov. 11 to 13 in Philadelphia.
Jeffrey L. Carson, M.D., from the Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey, and colleagues conducted a phase 3 interventional trial involving patients with myocardial infarction and a hemoglobin level of less than 10 g/dL. A total of 3,504 participants were randomly assigned to a restrictive transfusion strategy (hemoglobin cutoff for transfusion, 7 or 8 g/dL) or a liberal transfusion strategy (hemoglobin cutoff, <10 g/dL).
The researchers found that 16.9 percent of 1,749 patients in the restrictive-strategy group and 14.5 percent of 1,755 in the liberal-strategy group had a primary outcome event (composite of myocardial infarction or death at 30 days; risk ratio model with multiple imputation for incomplete follow-up, 1.15; 95 percent confidence interval, 0.99 to 1.34; P = 0.07). There was no significant difference seen in the occurrence of death or myocardial infarction with the restrictive strategy versus liberal strategy (9.9 versus 8.3 percent and 8.5 versus 7.2 percent, respectively).
"Trial end points suggest some benefit of a liberal strategy over a restrictive strategy, but additional studies would be needed to confirm that conclusion," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
ACC: Empagliflozin Does Not Cut Risk for Heart Failure After Acute MI
WEDNESDAY, April 10, 2024 -- Empagliflozin does not reduce the risk for first hospitalization for heart failure or death among patients at increased risk for heart failure after...
ACC: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI
MONDAY, April 8, 2024 -- For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a...
Iptacopan Improves Hematologic, Clinical Outcomes in Persistent Anemia
TUESDAY, March 19, 2024 -- The first-in-class oral factor B inhibitor iptacopan improves hematologic and clinical outcomes in anti-C5-treated patients with persistent anemia and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.